CohBar Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity

Jul 14, 2021

CohBar to Present at the BIO 2021 Digital Conference

Jun 10, 2021

CohBar Reports First Quarter 2021 Financial Results and Provides Business Update

May 17, 2021

CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021

May 3, 2021

CohBar Appoints Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director

Apr 27, 2021

CohBar Completes Last Subject Visit in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

Apr 21, 2021

CohBar to Present at the Mitochondria-Targeted Drug Development Summit

Apr 14, 2021

CohBar Reports Fourth Quarter 2020 Financial Results and Provides Business Update

Mar 30, 2021

CohBar Completes Enrollment in the Phase 1b Clinical Trial for CB4211 Under Development for NASH and Obesity

Mar 29, 2021

CohBar to Announce 2020 Fourth Quarter Financial Results and Provide Business Update on March 30, 2021

Mar 16, 2021